HOXB8 and osteosarcoma: The benefit of GSK‐J4 was validated in MTX‐ and cisplatin‐resistant osteosarcoma patients (same patient as Patient‐1 cells)‐derived xenograft (PDX) models (Figure 6g). Moreover, GSK‐J4 attenuated number of HOXB8 condensates in the nuclei of PDX tumor cells (Figure 6h).